Next Article in Journal
Strain-Specific Probiotic Properties of Bifidobacteria and Lactobacilli for the Prevention of Diarrhea Caused by Rotavirus in a Preclinical Model
Previous Article in Journal
What Serum Sodium Concentration Is Suggestive for Underhydration in Geriatric Patients?
Open AccessArticle

An Acute, Placebo-Controlled, Single-Blind, Crossover, Dose-Response, Exploratory Study to Assess the Effects of New Zealand Pine Bark Extract (Enzogenol®) on Glycaemic Responses in Healthy Participants

1
School of Health Sciences, Massey University, Auckland 0632, New Zealand
2
Waikato Medical Research Centre, University of Waikato, Hamilton 3216, New Zealand
3
School of Sport, Exercise and Nutrition, Massey University, Auckland 0632, New Zealand
4
School of Health Sciences, Massey University, Wellington 6021, New Zealand
5
Centre for Metabolic Health Research, Massey University, Auckland 0632, New Zealand
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(2), 497; https://doi.org/10.3390/nu12020497
Received: 7 January 2020 / Revised: 10 February 2020 / Accepted: 10 February 2020 / Published: 15 February 2020
(This article belongs to the Section Clinical Nutrition)
An acute, placebo-controlled, single-blind, crossover, dose-response, exploratory study was designed to investigate the hypoglycaemic effects of New Zealand pine bark extract (Enzogenol®). Twenty-five healthy participants categorised into having a monophasic or complex (biphasic or triphasic) glucose curve shape at the control visit consumed a placebo and Enzogenol® (50 and 400 mg) on three separate occasions before an oral glucose tolerance test (OGTT). In the monophasic group, 50 and 400 mg of Enzogenol® significantly reduced the mean glucose incremental area under the curve (iAUC) compared to control 241.3 ± 20.2 vs. 335.4 ± 34.0 mmol/L·min, p = 0.034 and 249.3 ± 25.4 vs. 353.6 ± 31.5 mmol/L·min, p = 0.012, respectively. The 400 mg dose further reduced the percentage increment of postprandial glucose (%PG) 31.4% ± 7.9% vs. 47.5% ± 8.6%, p = 0.010, glucose peak 7.9 ± 0.3 vs. 8.9 ± 0.3 mmol/L, p = 0.025 and 2h-OGTT postprandial glucose (2hPG) 6.1 ± 0.3 vs. 6.7 ± 0.3 mmol/L, p = 0.027. Glucose iAUC was not significantly different in the complex group, except for reductions in %PG 28.7% ± 8.2% vs. 43.4% ± 5.9%, p = 0.012 after 50 mg dose and 27.7% ± 5.4% vs. 47.3% ± 7.2%, p = 0.025 after 400 mg dose. The results suggest that Enzogenol® may have hypoglycaemic effects in healthy participants, especially those exhibiting monophasic shapes. View Full-Text
Keywords: New Zealand pine bark extract; Enzogenol®; proanthocyanidins; impaired glycaemic control; hypoglycaemic effects New Zealand pine bark extract; Enzogenol®; proanthocyanidins; impaired glycaemic control; hypoglycaemic effects
Show Figures

Figure 1

MDPI and ACS Style

Lim, W.X.J.; Chepulis, L.; von Hurst, P.; Gammon, C.S.; Page, R.A. An Acute, Placebo-Controlled, Single-Blind, Crossover, Dose-Response, Exploratory Study to Assess the Effects of New Zealand Pine Bark Extract (Enzogenol®) on Glycaemic Responses in Healthy Participants. Nutrients 2020, 12, 497.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop